4552 JCR Pharmaceuticals
- 614
- -6-0.97%
JCR Pharmaceuticals News
JCR Pharmaceuticals: Acceptance of clinical trial plan notifications for the JR-441 phase I trial against mucopolysaccharidosis type IIIA and completion of the agency investigation regarding the clinical trial plan
JCR Pharmaceuticals: Acceptance of clinical trial plan notifications for the JR-441 phase I trial against mucopolysaccharidosis type IIIA and completion of the agency investigation regarding the clinical trial plan
JCR Pharmaceuticals: [Delay] Financial Summary Consolidated Performance for the three months ended June 30, 2024 (Fiscal Year 2024) (Japanese standard)
JCR Pharmaceuticals: Announcements of individual stocks regarding the completion of payment for the disposal of treasury stock as stock compensation with transfer restrictions.
JCR Pharmaceuticals: 2024 Annual Q1 Earnings Conference Call
JCR Pharmaceuticals: Financial summary of the consolidated performance for the three months until June 30, 2024 (fiscal year 2024) (Japanese standard) (preliminary report).
JCR Pharmaceuticals: Overview of Q1 2025 earnings report.
JCR Pharmaceuticals: JCR Pharmaceuticals has announced the discontinuation of TEMCELL HS Inj manufacture, expanding the indications for developing neonatal hypoxic-ischemic encephalopathy.
JCR Pharmaceuticals: Announcements of individual stocks: Development of "Temcell HS injection" for neonatal hypoxic ischemic encephalopathy has been discontinued for expansion of indication (development code: JR-031HIE).
JCR Pharmaceuticals: Announcements of individual stocks regarding disposal of treasury stock as share-based compensation with transfer restrictions.
JCR Pharmaceuticals: JCR Pharmaceuticals emphasizes innovative gene therapy research at the 7th International Forum on Lysosomal Diseases.
JCR Pharmaceuticals: Announcements of individual stocks: Notice of research presentation at the 7th International Lysosomal Disease Forum.
JCR Pharmaceuticals: JCR held an API factory tour for local residents.
JCR Pharmaceuticals: We held a factory tour for local residents.
JCR Pharmaceuticals: Announcements of individual stock: [Delayed] Notice of personnel and organizational changes.
JCR Pharmaceuticals: Acceptance of the investigational plan for Phase I/II trials of JR-446 for Mucopolysaccharidosis IIIB and completion of regulatory authority investigation regarding the clinical trial plan.
JCR Pharmaceuticals: MEDIPAL and JCR have announced the completion of the clinical trial notification process for the phase I/II trial of JR-446 for mucopolysaccharidosis type IIIB in Japan.
JCR Pharmaceuticals: Announcements of individual stocks regarding personnel changes and organizational restructuring.
JCR Pharmaceuticals: Matters related to the controlling shareholder (affiliated company).
JCR Pharmaceuticals: Regarding matters related to major shareholders (other affiliated companies).
Analysis
Price Target
No Data
